Have a High Threshold in Transfusing Platelets, Especially in Nonbleeding Patients who are not Preoperative
Michael J. Haut MD
Platelet transfusion has made a significant contribution to the care of certain patient populations. These groups include those undergoing high-dose chemotherapy (e.g., for acute leukemia or stem cell transplant) and patients sustaining major trauma. Platelets for transfusion are obtained either by centrifugation of units of whole blood (random donor platelets) or by pheresis. In general, units available in the United States are leukoreduced. Leukoreduction reduces the incidence of platelet transfusion reactions and may reduce the incidence of alloimmunization.
What to Do
Considerable effort has gone into determining what the trigger should be for the transfusion of platelets and how many platelets should be transfused. Historically, the platelet transfusion trigger for patients with chemotherapy-induced thrombocytopenia was 20 × 109/μL. However, several recent large studies have suggested that 10 × 109/μL is acceptable. A large retrospective study has shown that the most significant predictor of bleeding in thrombocytopenic patients is not the platelet count but a history of bleeding in the previous 5 days. These data suggest that attention should be focused on providing aggressive platelet therapy for active bleeding rather than on prophylactically transfusing platelets. Such an approach may not be appropriate in trauma patients, in whom hypothermia, acidosis, and other factors may affect the function of the patient’s own platelets and the platelets that are transfused. Specific situations requiring platelet transfusions in thrombocytopenic patients include the presence of bleeding and the need to perform invasive procedures such as lumbar puncture, bronchoscopy, and surgery.